Dr Lal Pathlabs Ltd logo

Dr Lal Pathlabs Ltd

LALPATHLAB NSE

Key Fundamentals

SmallcapHealthcare Service ProviderHealthcare Services
Market Cap
₹32,430 Cr
Volatility
High Risk
P/E Ratio
59.73
EBITDA
₹884 Cr
Return on Equity
20.06%
Debt to Equity
0.08
Book Value
₹149.62
EPS
₹45.65
52W High
₹1,955.1
52W Low
₹1,272.6

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Dr Lal Pathlabs Ltd insights

45 extracted metrics + investor summaries across FY14–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 36.4%

Weaknesses

2
  • Stock is trading at 12.9 times its book value
  • The company has delivered a poor sales growth of 11.8% over past five years.

Growth Rate

Revenue Growth
12.11% ↘
Net Income Growth
3.55% ↘
Cash Flow Change
11.73% ↗
ROE
-10.09% ↘
ROCE
-8.19% ↘
EBITDA Margin (Avg.)
-0.06% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 3d ago
AI opinion · based on fundamentals
Risk medium

Dr Lal Pathlabs Ltd is a nearly debt-free diagnostics leader trading at a market cap of ₹31,786 Cr with a PE of 57.9x and consistent ROE of 22%. Revenue has compounded at 13% over 10 years while profit growth stands at 15% CAGR over the same period, though the stock has delivered negative 1% CAGR over 5 years.

Bull Case 8
  • Company is virtually debt-free, providing financial flexibility and resilience during downturns with a negligible debt-to-equity ratio
  • Consistent return on equity of 22% maintained over 3, 5, and 10-year periods, indicating efficient capital allocation
  • 10-year compounded profit growth of 15% demonstrates sustained earnings power over a long horizon
  • TTM revenue growth of 14% shows acceleration relative to the 5-year sales CAGR of 12%, suggesting improving momentum
  • Healthy dividend payout ratio of 36.4% reflects shareholder-friendly capital return policy despite being a growth business
  • 3-year compounded profit growth of 30% indicates strong post-COVID earnings recovery and operating leverage
  • Stock has delivered 18% returns over the last 1 year and 17% CAGR over 3 years, showing renewed investor interest
  • 10-year sales CAGR of 13% demonstrates the company's ability to grow consistently through multiple economic cycles
Bear Case 8
  • PE ratio of 57.9x is significantly elevated relative to broader market averages, leaving limited margin of safety
  • Stock trades at 12.6x book value, reflecting a rich valuation that prices in substantial future growth
  • 5-year stock CAGR of negative 1% indicates the market has not rewarded shareholders over a meaningful holding period
  • 5-year compounded sales growth of only 11.8% is modest for a company commanding a 57.9x earnings multiple
  • Dividend yield of just 0.26% offers negligible income support at current elevated valuations
  • TTM profit growth of 10% is decelerating sharply compared to the 3-year CAGR of 30%, suggesting normalizing earnings trajectory
  • 5-year profit CAGR of 12% is only marginally ahead of the 12% sales CAGR, indicating limited operating leverage expansion over that period
  • At ₹31,786 Cr market cap with 14% TTM revenue growth, the valuation assumes sustained high growth that any execution miss could derail

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 1d ago
Positives 6
  • Q1FY27 profit surges 27% Jul 30

    Consolidated net profit jumped 27.2% to ₹1,705 crore on 18.9% revenue growth to ₹8,296 crore. EBITDA grew 28.7% to ₹2,564 crore with margins expanding to 30.9%.

  • Mid-teens revenue growth signaled Jul 27

    Management hinted at upgrading revenue growth guidance to mid-teens from prior 6-7% patient volume growth, with EBITDA margin at 27-28% and scope for upward revision post-Q2.

  • Expansion via labs and radiology Jul 27

    Plans to add 12-15 new labs and 3-4 radiology centers backed by ₹140-150 crore capex. Extra margin gains earmarked for reinvestment.

  • ESOP tax appeal win Jul 17

    Income Tax appellate order decided in company's favour on ESOP expenses of ₹32.66 crore.

  • Dividends of ₹9 per share Jul 30

    Declared ₹5 interim dividend alongside Q1 results and ₹4 final dividend for FY26 approved at AGM on Jul 25.

  • Strategic acquisitions announced Jul 30

    Acquired stakes in Sunshine Healthcare and Neuome Technologies to strengthen capabilities and network.

Neutral 2
  • Director Kalra completes tenure Jul 26

    Independent director Gurinder Singh Kalra stepped down on July 26, 2026 after completing his tenure.

  • International growth below 5% Jul 27

    International business growth expected to remain below 5% over the next 2-3 years, with focus primarily on domestic expansion.

TL;DR: Dr Lal PathLabs delivered a standout Q1FY27 with 27% profit growth and margin expansion to 30.9%, signaling strong operational momentum. Management is guiding toward mid-teens revenue growth with further margin upside possible post-Q2. No material headwinds are visible — the only constraint is muted international growth below 5%. The trend is clearly improving with accelerating volumes, expanding margins, and reinvestment into new labs and radiology centers.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
541
601
539
545
602
660
597
603
670
731
660
703
798
Expenses
395
424
398
401
432
458
443
434
478
506
480
516
550
Operating Profit
146
178
141
145
170
202
154
169
192
224
179
187
248
OPM %
27%
30%
26%
27%
28%
31%
26%
28%
29%
31%
27%
27%
31%
Other Income
14
18
18
18
21
22
25
26
28
25
-6
24
32
Interest
8
8
7
7
6
6
5
5
5
5
7
6
6
Depreciation
35
36
36
37
35
35
36
36
35
40
42
45
44
PBT
118
152
116
120
150
183
138
153
181
204
124
160
229
Tax %
29%
27%
29%
28%
28%
29%
29%
-1%
26%
25%
26%
17%
25%
Net Profit
84
111
82
86
108
131
98
156
134
152
91
132
170
EPS in Rs
4.95
6.55
4.87
5.06
6.37
7.73
5.78
9.26
7.9
8.99
5.4
7.84
10.11
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
660
791
912
1,057
1,203
1,330
1,581
2,087
2,017
2,227
2,461
2,763
2,891
Expenses
504
582
675
793
910
987
1,145
1,526
1,527
1,617
1,764
1,979
2,053
Operating Profit
156
210
238
264
294
344
436
561
490
609
698
783
838
OPM %
24%
26%
26%
25%
24%
26%
28%
27%
24%
27%
28%
28%
29%
Other Income
12
20
27
31
46
55
51
52
42
69
91
70
75
Interest
0
0
1
1
1
15
16
30
38
29
22
23
24
Depreciation
28
28
28
33
38
73
77
108
150
144
142
162
172
PBT
140
201
237
261
301
310
394
475
344
505
625
669
717
Tax %
31%
34%
34%
34%
33%
27%
25%
26%
30%
28%
21%
24%
—
Net Profit
96
133
156
172
200
228
296
350
241
362
492
510
546
EPS in Rs
8.75
7.99
9.31
10.24
11.95
13.55
17.49
20.69
14.33
21.42
29.14
30.13
32.34
Div. Payout %
9%
15%
16%
22%
25%
44%
57%
29%
42%
0%
41%
68%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
55
83
83
83
83
83
83
83
83
83
84
168
Reserves
260
425
512
705
862
949
1,162
1,418
1,583
1,766
2,089
2,341
Borrowings
27
0
0
0
0
0
150
533
420
247
157
199
Other Liabilities
134
118
95
128
145
341
265
309
297
357
383
433
Total Liabilities
475
625
690
916
1,091
1,374
1,661
2,343
2,383
2,454
2,713
3,140
Fixed Assets
150
166
152
208
209
413
447
1,369
1,305
1,228
1,168
1,256
CWIP
1
4
18
10
3
11
10
15
5
6
3
7
Investments
38
64
106
145
185
164
59
65
150
114
327
423
Other Assets
286
391
414
554
694
786
1,144
893
923
1,107
1,215
1,454
Total Assets
475
625
690
916
1,091
1,374
1,661
2,343
2,383
2,454
2,713
3,140
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
122
159
171
197
219
284
398
447
456
535
569
636
Investing
-113
-163
-137
-172
-100
-26
-212
-449
-287
-24
-303
-422
Financing
-1
0
-32
13
-55
-190
-139
136
-283
-414
-334
-264
Net Cash Flow
8
-5
2
37
64
67
48
134
-114
97
-68
-50
Free Cash Flow
87
115
120
125
177
205
339
-28
412
479
516
463
CFO/OP
112
108
102
110
110
110
115
103
115
110
105
104
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
17
17
17
14
16
14
15
15
13
13
13
15
Inventory Days
37
31
33
44
40
70
39
38
28
30
27
30
Days Payable
90
89
97
106
111
144
132
107
127
151
127
123
Cash Conversion Cycle
-35
-42
-47
-47
-55
-60
-78
-54
-87
-108
-86
-79
Working Capital Days
-9
27
19
17
0
-19
-26
-54
-56
-46
-30
-29
ROCE %
48%
47%
43%
38%
35%
32%
33%
29%
18%
25%
29%
28%

Shareholding Pattern

As of Jun 2026
Promoters 53.19%
DIIs 21.59%
FIIs 17.36%
Public 6.25%
Others 1.60%
Government 0.01%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
55.23%
55.23%
55.23%
55.23%
55.23%
55.05%
55.05%
55.05%
55.03%
55.01%
54.61%
54.60%
54.60%
54.60%
53.92%
53.91%
53.91%
53.79%
53.21%
53.21%
53.21%
53.19%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
2.00%
1.83%
0.00%
0.00%
0.00%
26.15%
25.42%
26.82%
26.82%
23.91%
21.68%
21.86%
20.29%
17.18%
17.36%
DIIs
6.47%
5.61%
4.84%
5.58%
5.69%
5.30%
5.09%
6.19%
6.55%
7.33%
7.97%
8.61%
9.69%
12.71%
12.89%
13.17%
16.08%
17.91%
18.49%
19.21%
21.38%
21.59%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.01%
0.01%
0.01%
Public
5.70%
6.24%
6.93%
7.45%
9.03%
10.44%
8.24%
9.03%
9.50%
9.31%
8.37%
7.26%
6.47%
4.91%
4.10%
4.01%
4.11%
5.23%
5.19%
5.82%
6.54%
6.25%
Others
32.60%
32.92%
32.99%
31.74%
30.05%
29.22%
31.63%
27.73%
27.09%
28.35%
29.05%
29.53%
3.09%
2.35%
2.27%
2.10%
2.00%
1.38%
1.25%
1.47%
1.67%
1.60%
No. of Shareholders
68,845
94,123
1,25,953
1,35,068
1,71,846
1,84,508
1,71,602
1,79,636
1,80,163
1,74,444
1,60,679
1,49,901
1,46,741
1,31,189
1,16,606
1,16,236
1,15,699
1,18,656
1,12,703
1,14,385
1,14,527
1,11,037

Documents

Frequently Asked Questions about Dr Lal Pathlabs Ltd

What does Dr Lal Pathlabs Ltd do?
Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient...
Where is Dr Lal Pathlabs Ltd (LALPATHLAB) listed?
Dr Lal Pathlabs Ltd is listed on the Indian stock exchanges. It is listed on NSE: LALPATHLAB and BSE: 539524. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Dr Lal Pathlabs Ltd belong to?
Dr Lal Pathlabs Ltd operates in the Healthcare Services sector within the Healthcare Service Provider industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Dr Lal Pathlabs Ltd?
Dr Lal Pathlabs Ltd has a market capitalisation of approximately ₹32429.53 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Dr Lal Pathlabs Ltd?
The Price-to-Earnings (PE) ratio of Dr Lal Pathlabs Ltd is 59.73. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Dr Lal Pathlabs Ltd?
Over the past 52 weeks, Dr Lal Pathlabs Ltd has traded between a low of ₹1,272.6 and a high of ₹1,955.1. This range helps investors understand the stock's price volatility and recent trading levels.
Does Dr Lal Pathlabs Ltd pay dividends?
Yes, Dr Lal Pathlabs Ltd has a dividend yield of 0.26%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Dr Lal Pathlabs Ltd?
Dr Lal Pathlabs Ltd has a Return on Equity (ROE) of 20.06%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Dr Lal Pathlabs Ltd on Tapetide?
On Tapetide, you can view Dr Lal Pathlabs Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. [1]

Website lalpathlabs.com
Listed 2015-12-23
Face Value ₹ 10
Issued Size 16,75,51,020

Explore More

More in Healthcare Services → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List